TME Pharma expands AI-driven drug discovery with Aimed Analytics partnership
TME Pharma, a biotechnology company pioneering therapies that target the tumor microenvironment, has announced a strategic collaboration with aimed analytics, a specialist in AI-driven medical ... Read More
Immunomic Therapeutics begins ITI-1001 Phase 1 trial in glioblastoma
Immunomic Therapeutics, Inc., a clinical-stage biotech company specializing in nucleic acid immunotherapy platforms, has dosed the first patient in a Phase 1 clinical trial of ... Read More
Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type ... Read More
Kazia Therapeutics gets fast track status for paxalisib in glioblastoma
Kazia Therapeutics, an Australian oncology company, has secured fast track designation (FTD) from the US Food and Drug Administration (FDA) for paxalisib (formerly GDC-0084) for ... Read More
Denovo Biopharma gets FDA approval to launch phase 2b GBM trial for DB102
Denovo Biopharma has secured approval from the US Food and Drug Administration (FDA) to launch its phase 2b clinical trial of DB102 in patients with ... Read More